iTeos Therapeutics to Participate in Upcoming September Investor Conferences
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Sept. 01, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immune-oncology therapeutics for patients, today announced that company management will participate in five upcoming virtual investor conferences in September:
- KBC Securities Life Sciences Conference
Format: Management one-on-ones
Date: September 7, 2021
- Wells Fargo Virtual Healthcare Conference
Format: Management one-on-ones
Date: September 9-10, 2021
- Morgan Stanley 19th Annual Global Healthcare Conference
Format: Management one-on-ones
Date: September 9-10 and 13-15, 2021
- H.C. Wainwright 23rd Annual Global Investment Conference
Format: On demand presentation by Michel Detheux, Ph.D., President and Chief Executive Officer
Date/Time: Monday, September 13, 2021 at 7:00 a.m. ET
- Cantor Fitzgerald Global Healthcare Conference
Format: Live presentation by Michel Detheux, Ph.D., President and Chief Executive Officer
Date/Time: Monday, September 27, 2021 at 2:40 p.m. ET
Audio webcasts of the presentations will be available on the Investor section of the company’s website at https://www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. The Company’s innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology. The initial antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism. An open-label Phase 1 clinical trial of EOS-448 is ongoing in adult cancer patients with advanced solid tumors with preliminary data indicating preliminary clinical activity as a monotherapy and a favorable tolerability profile. The Company is also advancing inupadenant, a first insurmountable adenosine A2A receptor antagonist in clinical development tailored to overcome cancer immunosuppression. iTeos is conducting an open-label multi-arm Phase 1/2a clinical trial of inupadenant in adult cancer patients with advanced solid tumors. Preliminary results indicate encouraging single-agent activity as well as the identification of a potential predictive biomarker. iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.
For further information, please contact:
Investor Contact:
Ryan Baker
iTeos Therapeutics, Inc.
Ryan.Baker@iteostherapeutics.com
Media Contact:
media@iteostherapeutics.com
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
EPH European Property Holdings PLC announces 2023 Year-End Result26.4.2024 23:55:00 CEST | Press release
26 April 2024, Limassol, Cyprus / Ad hoc announcement pursuant to Art. 53 LR BUSINESS HIGHLIGHTS 2023 Despite the challenging market environment, EPH European Property Holdings PLC (“EPH” or the “Company”) maintained operational stability in 2023. This success can be attributed to its established portfolio of high-quality properties in prime locations in Europe, and professional asset management. As a result, EPH once again achieved almost full occupancy throughout its European portfolio, and exceeded own expectations by increasing net rental income by 26 percent compared to the previous year.As of 31 December 2023, EPH’s real estate portfolio consisted of eight core assets (and one parking garage) in outstanding locations in Germany and Vienna, all of which meet high sustainability standards. Seven out of eight office and hotel buildings have already been awarded certificates in DGNB Platinum, DGNB Gold, or LEED Gold.A milestone in the operating business was the completion of the LASS
FRO – Filing of Annual Report26.4.2024 22:36:43 CEST | Press release
Frontline plc (the “Company”) announces the filing of its annual report for the year ended December 31, 2023. The annual report can be downloaded from the Company’s website www.frontlineplc.cy or from the link below. Additionally, shareholders can request a hard copy of our complete audited financial statements free of charge by writing to us at: John Kennedy 8 Iris Building, 7th floor, Flat/Office 740B, 3106, Limassol, Cyprus. or sending an e-mail to ir@frontmgt.no April 26, 2024 Frontline plc Limassol, Cyprus. Questions should be directed to: Lars H. Barstad: Chief Executive Officer, Frontline Management AS +47 23 11 40 00 Inger M. Klemp: Chief Financial Officer, Frontline Management AS +47 23 11 40 00 This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. Attachments 5493004BCIKYU1YL3H63-2023-12-31-enAnnual Report 2023
Kallelse till årsstämma 2024 i Fingerprint Cards AB (publ)26.4.2024 22:16:32 CEST | Pressemelding
Aktieägarna i Fingerprint Cards AB (publ), org. nr. 556154-2381 (”Bolaget” eller ”Fingerprint”), kallas härmed till årsstämma klockan 15.00 tisdagen den 28 maj 2024 på GT30 (mötesrum ”Bond”), Grev Turegatan 30 i Stockholm. Styrelsen har, i enlighet med Bolagets bolagsordning, beslutat att aktieägarna före årsstämman ska ha möjlighet att utöva sin rösträtt genom poströstning. Aktieägare kan därmed välja att utöva sin rösträtt vid stämman personligen, genom ombud eller genom poströstning. A. Rätt att delta på stämman Aktieägare som önskar delta vid årsstämman ska: vara införd i den av Euroclear Sweden AB förda aktieboken måndagen den 20 maj 2024, och anmäla sin avsikt att delta vid stämman till Bolaget i enlighet med anvisningarna under avsnitt ”B. Anmälan för deltagande personligen eller genom ombud” senast onsdagen den 22 maj 2024, eller avge en poströst i enlighet med anvisningarna under rubriken ”C.Anvisningar för poströstning” senast onsdagen den 22 maj 2024. För att ha rätt att del
Notice to attend the 2024 Annual General Meeting of Fingerprint Cards AB (publ)26.4.2024 22:16:32 CEST | Press release
The shareholders of Fingerprint Cards AB (publ), Corp. Reg. No. 556154-2381 (hereinafter referred to as the “Company” or “Fingerprint”)), are hereby invited to attend the Annual General Meeting (“AGM” or the “Meeting”) to be held at 3:00 p.m. on Tuesday, May 28, 2024, at GT30 (meeting room “Bond”), Grev Turegatan 30 in Stockholm. The Board of Directors has decided, pursuant to the Company’s articles of association, that shareholders shall also have the right to exercise their voting rights by postal voting. Shareholders may therefore choose to exercise their voting rights at the Meeting by attending in person, through a proxy or by postal voting. A. Right to participate in the Meeting In order to participate in the Meeting, a shareholder shall: be registered in the register of shareholders maintained by Euroclear Sweden AB as of Monday, May 20, 2024, and give notice of attendance at the Meeting to the Company in accordance with the instructions set out in the section “B. Notice of atte
Fingerprints announces partially guaranteed rights issue of up to approximately SEK 310 million, agreement on early redemption of its convertible bonds, bridge loan of SEK 60 million and preliminary financial information for Q1 202426.4.2024 22:00:00 CEST | Press release
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL. PLEASE SEE "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE. The Board of Directors of Fingerprint Cards AB ("Fingerprints" or the "Company") has resolved on a partially guaranteed issue of new shares of series B (“B-shares”) of up to approximately SEK 310 million with preferential rights for its existing shareholders, subject to subsequent approval from the annual general meeting in the Company to be held on 28 May 2024 (the “Rights Issue”). The Rights Issue is subject to subscription undertakings and guarantee commitments in a total amount of up to SEK 275 million. The Board of Directors of Fingerprints has also entered into an agreement with an entity managed by